$CTGO
Contango ORE, Inc. Stock $ctgo

$ctgo Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000143774923031883 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.200M	$2.770M	$2.510M
YoY Change	47.04%	14.27%	7.2%
% of Gross Profit
Research & Development	$862.0K	$1.210M	$1.137M
YoY Change	-63.26%	-73.37%	-74.86%
% of Gross Profit
Depreciation & Amortization	$22.62K	$26.00K	$33.86K
YoY Change	-33.9%	-24.02%	6.51%
% of Gross Profit
Operating Expenses	$4.088M	$4.000M	$3.681M
YoY Change	-10.28%	-39.97%	-46.62%
Operating Profit		-$9.615M
YoY Change
Interest Expense	-$22.88M	-$9.150M	-$7.334M
YoY Change	134.65%	-2135.73%	2148.0%
% of Operating Profit
Other Income/Expense, Net	$140.1K	-$9.144M	$606.5K
YoY Change	-101.44%	10413.92%	1363.21%
Pretax Income	-$27.62M	-$13.15M	-$10.42M
YoY Change	93.01%	85.43%	44.03%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$27.62M	-$13.15M	-$10.42M
YoY Change	93.01%	85.42%	44.03%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.47	-$1.38
Diluted Earnings Per Share	-$2.79	-$1.47	-$1.38
COMMON SHARES
Basic Shares Outstanding	9.400M	9.394M	7.620M
Diluted Shares Outstanding		8.936M	7.547M

Balance Sheet

Concept	2023 Q4	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.50M	$18.51M	$11.65M
YoY Change	76.89%	3.93%	-49.57%
Cash & Equivalents	$15.50M	$18.51M	$11.65M
Short-Term Investments
Other Short-Term Assets	$1.345M	$1.580M	$644.9K
YoY Change	28.43%	135.48%	-5.76%
Inventory
Prepaid Expenses	$1.113M	$795.1K	$413.9K
Receivables
Other Receivables
Total Short-Term Assets	$16.85M	$20.08M	$12.29M
YoY Change	71.72%	8.67%	-48.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.33M	$13.35M	$13.37M
YoY Change	-0.9%	-0.95%	-1.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$28.06M	$21.42M	$0.00
YoY Change
Other Assets	$350.6K	$34.77M	$13.37M
YoY Change	-97.39%	157.96%	-1.06%
Total Long-Term Assets	$41.74M	$34.77M	$13.37M
YoY Change	210.42%	157.96%	-1.06%
TOTAL ASSETS
Total Short-Term Assets	$16.85M	$20.08M	$12.29M
Total Long-Term Assets	$41.74M	$34.77M	$13.37M
Total Assets	$58.59M	$54.86M	$25.66M
YoY Change	151.9%	71.63%	-31.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$250.7K	$2.129M	$220.8K
YoY Change	66.41%	75.93%	-65.17%
Accrued Expenses	$2.241M	$871.7K	$2.078M
YoY Change	78.6%	-21.06%	138.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.900M	$2.000M	$0.00
YoY Change
Total Short-Term Liabilities	$13.07M	$5.001M	$2.299M
YoY Change	830.02%	116.06%	52.75%
LONG-TERM LIABILITIES
Long-Term Debt	$36.78M	$32.86M	$25.46M
YoY Change	90.07%	70.35%	32.31%
Other Long-Term Liabilities	$23.28M	$5.960M	$2.681M
YoY Change	609.66%	81.81%	-18.16%
Total Long-Term Liabilities	$60.06M	$38.81M	$28.14M
YoY Change	165.4%	72.01%	24.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.07M	$5.001M	$2.299M
Total Long-Term Liabilities	$60.06M	$38.81M	$28.14M
Total Liabilities	$73.14M	$43.81M	$30.44M
YoY Change	204.27%	76.11%	26.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$139.0M	-$111.4M	-$98.28M
YoY Change	73.94%	69.79%	67.89%
Common Stock	$124.5M	$122.5M	$93.50M
YoY Change	57.48%	63.65%	26.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$14.54M	$11.04M	-$4.773M
YoY Change
Total Liabilities & Shareholders Equity	$58.59M	$54.86M	$25.66M
YoY Change	151.9%	71.63%	-31.19%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$27.62M	-$13.15M	-$10.42M
YoY Change	93.01%	85.42%	44.03%
Depreciation, Depletion And Amortization	$22.62K	$26.00K	$33.86K
YoY Change	-33.9%	-24.02%	6.51%
Cash From Operating Activities	-$5.882M	-$3.552M	-$1.106M
YoY Change	11.18%	-32.41%	-76.45%
INVESTING ACTIVITIES
Capital Expenditures	-$2.670K	$6.995K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$7.350M	-$27.03M	-$6.720M
YoY Change	-21.05%
Cash From Investing Activities	-$7.347M	-$27.04M	-$6.720M
YoY Change	-21.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.23M	$37.45M	16.55M
YoY Change	84.12%	-123173.78%	-16.42%
NET CHANGE
Cash From Operating Activities	-5.882M	-$3.552M	-1.106M
Cash From Investing Activities	-7.347M	-$27.04M	-6.720M
Cash From Financing Activities	10.23M	$37.45M	16.55M
Net Change In Cash	-3.000M	$6.861M	8.727M
YoY Change	-66.83%	-229.81%	-42.24%
FREE CASH FLOW
Cash From Operating Activities	-$5.882M	-$3.552M	-$1.106M
Capital Expenditures	-$2.670K	$6.995K	$0.00
Free Cash Flow	-$5.880M	-$3.559M	-$1.106M
YoY Change	11.13%	-32.27%	-76.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001502377
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9393922
CY2023Q3	dei	Entity Registrant Name EntityRegistrantName	Contango ORE, Inc.
CY2023Q3	dei	Amendment Flag AmendmentFlag	false
CY2023Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9395112
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2298625	usd
CY2023Q3	ctgo	Advance Royalty Reimbursement Noncurrent AdvanceRoyaltyReimbursementNoncurrent	1200000	usd
CY2023Q2	ctgo	Advance Royalty Reimbursement Noncurrent AdvanceRoyaltyReimbursementNoncurrent	1200000	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7781690
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7781690
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1190
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0
CY2020Q4	ctgo	Rights Agreement Number Of Preferred Stock Issuable Per Right RightsAgreementNumberOfPreferredStockIssuablePerRight	0.001
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q3	dei	Document Type DocumentType	10-Q
CY2023Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q3	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q3	dei	Entity File Number EntityFileNumber	001-35770
CY2023Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3431051
CY2023Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	3700 BUFFALO SPEEDWAY, SUITE 925
CY2023Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
CY2023Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77098
CY2023Q3	dei	City Area Code CityAreaCode	713
CY2023Q3	dei	Local Phone Number LocalPhoneNumber	877-1311
CY2023Q3	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 per share
CY2023Q3	dei	Trading Symbol TradingSymbol	CTGO
CY2023Q3	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q3	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9400128
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18507308	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11646194	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	231000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	231000	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	795111	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	413907	usd
CY2023Q3	us-gaap	Derivative Assets Current DerivativeAssetsCurrent	549116	usd
CY2023Q2	us-gaap	Derivative Assets Current DerivativeAssetsCurrent	0	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	20082535	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	12291101	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	21420712	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13352637	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13371638	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34773349	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13371638	usd
CY2023Q3	us-gaap	Assets Assets	54855884	usd
CY2023Q2	us-gaap	Assets Assets	25662739	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2129361	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	220755	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	871728	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2077870	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5001089	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7091770	usd
CY2023Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	243126	usd
CY2023Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	239942	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1240563	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1240563	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3274527	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	32855385	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25457047	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	38813601	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	28137552	usd
CY2023Q3	us-gaap	Liabilities Liabilities	43814690	usd
CY2023Q2	us-gaap	Liabilities Liabilities	30436177	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	93951	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	77817	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	122393198	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	93424283	usd
CY2023Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	21190	usd
CY2023Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	-0	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111424765	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98275538	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	11041194	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4773438	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54855884	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25662739	usd
CY2023Q3	ctgo	Claim Rental Expense ClaimRentalExpense	127006	usd
CY2022Q3	ctgo	Claim Rental Expense ClaimRentalExpense	146925	usd
CY2023Q3	us-gaap	Exploration Expense ExplorationExpense	1081927	usd
CY2022Q3	us-gaap	Exploration Expense ExplorationExpense	4396570	usd
CY2023Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	25997	usd
CY2022Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	34214	usd
CY2023Q3	us-gaap	Accretion Expense AccretionExpense	3183	usd
CY2022Q3	us-gaap	Accretion Expense AccretionExpense	3026	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2767477	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2424068	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	4005590	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	7004803	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	39045	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	8546	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-847983	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-449470	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5609288	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2023Q3	us-gaap	Insurance Recoveries InsuranceRecoveries	0	usd
CY2022Q3	us-gaap	Insurance Recoveries InsuranceRecoveries	338301	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-2725411	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	15656	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9143637	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-86967	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-13149227	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	787874	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.47
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8935863
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6771245
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-13149227	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7091770	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	739783	usd
CY2023Q3	us-gaap	Depreciation Depreciation	25997	usd
CY2022Q3	us-gaap	Depreciation Depreciation	34214	usd
CY2023Q3	us-gaap	Accretion Expense AccretionExpense	3183	usd
CY2022Q3	us-gaap	Accretion Expense AccretionExpense	3026	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5609288	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-0	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-2725411	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-0	usd
CY2023Q3	us-gaap	Paid In Kind Interest PaidInKindInterest	66658	usd
CY2022Q3	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	105633	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	49471	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	381203	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13384	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	702464	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	948756	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3552013	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5255045	usd
CY2023Q3	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	27030000	usd
CY2022Q3	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	-0	usd
CY2023Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6995	usd
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27036995	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q3	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	21190	usd
CY2022Q3	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	27693	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q3	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	707296	usd
CY2022Q3	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2736	usd
CY2023Q3	ctgo	Proceeds From Repurchase Of Capital Raises Net ProceedsFromRepurchaseOfCapitalRaisesNet	28178608	usd
CY2022Q3	ctgo	Proceeds From Repurchase Of Capital Raises Net ProceedsFromRepurchaseOfCapitalRaisesNet	0	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37450122	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-30429	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6861114	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5285474	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11877194	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23326101	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18738308	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18040627	usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet	472184	usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet	416670	usd
CY2023Q3	us-gaap	Stock Issued1 StockIssued1	66658	usd
CY2022Q3	us-gaap	Stock Issued1 StockIssued1	138886	usd
CY2023Q3	ctgo	Fair Value Of Investing Activities Assumed FairValueOfInvestingActivitiesAssumed	66658	usd
CY2022Q3	ctgo	Fair Value Of Investing Activities Assumed FairValueOfInvestingActivitiesAssumed	138886	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4773438	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	739783	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30400000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2221392	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	66658	usd
CY2023Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	21190	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-13149227	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	11041194	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	13274043	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	787874	usd
CY2022Q3	ctgo	Stock Issued During Period Shares Treasury Stock Reissued Value StockIssuedDuringPeriodSharesTreasuryStockReissuedValue	138886	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	27693	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7091770	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	7081340	usd
CY2023Q3	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em> Basis of Presentation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:24pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), including instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">8</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by US GAAP for complete annual consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial statements have been included. All such adjustments are of a normal recurring nature. The consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes included in the Company’s Form <em style="font: inherit;">10</em>-K for the fiscal year ended <em style="font: inherit;"> June 30, 2023</em>. The results of operations for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2023</em> are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>be expected for the fiscal year ending <em style="font: inherit;"> June </em><em style="font: inherit;">30,</em> <em style="font: inherit;">2024.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:24pt;"> </p>
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	795111	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	413907	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13149227	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8935863
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.47
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7091770	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6771245
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13149227	usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8935863
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.47
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7091770	usd
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6771245
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	501000
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	436183
CY2023Q3	ctgo	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Warrants Outstanding Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndWarrantsOutstandingNumber	501000
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY223Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	ctgo	Rights Agreement Exercise Price RightsAgreementExercisePrice	100
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	218238	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	192241	usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	122136	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	122136	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13352637	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13371638	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	100000
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	739783	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	787784	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2666958	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y3M7D
CY2019Q1	ctgo	Contingent Salary And Compensation Retention Agreement ContingentSalaryAndCompensationRetentionAgreement	1500000	usd
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	34855385000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	25457047000	usd
CY2023Q3	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	-2725411	usd
CY2023Q3	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	-2725411	usd

Files In Submission

Name	View Source	Status
0001437749-23-031883-index-headers.html	Edgar Link	pending
0001437749-23-031883-index.html	Edgar Link	pending
0001437749-23-031883.txt	Edgar Link	pending
0001437749-23-031883-xbrl.zip	Edgar Link	pending
conta20230930_10q.htm	Edgar Link	pending
ctgo-20230930.xsd	Edgar Link	pending
ex_582982.htm	Edgar Link	pending
ex_582983.htm	Edgar Link	pending
ex_582984.htm	Edgar Link	pending
ex_582985.htm	Edgar Link	pending
ex_595206.htm	Edgar Link	pending
ex_595211.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
ctgo-20230930_def.xml	Edgar Link	unprocessable
ctgo-20230930_lab.xml	Edgar Link	unprocessable
ctgo-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
conta20230930_10q_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ctgo-20230930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTGO
Contango ORE, Inc. Stock $ctgo

2023 Q4 Form 10-Q Financial Statement

#000143774923031883 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTGO Contango ORE, Inc. Stock $ctgo

2023 Q4 Form 10-Q Financial Statement

#000143774923031883 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTGO
Contango ORE, Inc. Stock $ctgo